Lv51
910 积分 2023-03-20 加入
The cytoplasmic body component TRIM5α restricts HIV-1 infection in Old World monkeys
2小时前
已完结
DB-1314, a novel DLL3-targeting ADC with DNA topoisomerase I inhibitor, exhibits promising safety profile and therapeutic efficacy in preclinical small cell lung cancer models
11天前
已完结
Off-the-shelf CAR T cells for refractory autoimmunity
14天前
已完结
Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia
19天前
已完结
OA10.05 Phase I Trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3-Positive Tumors: Patients with LCNEC
1个月前
已完结
686TiP Preliminary phase I results from a first-in-human study of ZG006, a trispecific anti-T cell engager targeting CD3/DLL3/DLL3, as monotherapy in patients with advanced small cell lung cancer or neuroendocrine carcinoma
1个月前
已完结
OA10.05 Phase I Trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3-Positive Tumors: Patients with LCNEC
1个月前
已关闭
Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion
1个月前
已完结
Cutaneous manifestations of chimeric antigen receptor T-cell therapy: An introduction for dermatologists
1个月前
已完结
Dermatologic adverse events associated with chimeric antigen receptor T-cell therapy: a pharmacovigilance analysis of the FDA reporting system
1个月前
已完结
皖公网安备34019202002308
